Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
Yan-Ruide Li, Samuel Zeng, Zachary Spencer Dunn, Yang Zhou, Zhe Li, Jiaji Yu, Yu-Chen Wang, Josh Ku, Noah Cook, Adam B. Kramer, Lili Yang
Abstract
HSC-iNKT cells as a promising off-the-shelf cell therapy candidate for GvHD prophylaxis.
Topics & Concepts
ImmunologyCD8Natural killer T cellCD1DCancer researchMedicineLeukemiaBiologyImmune systemImmune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell Immunology